Ki67 as a Predictor of Response to PARP Inhibitors in Platinum Sensitive BRCA Wild Type Ovarian Cancer: The MITO 37 Retrospective Study.
Valentina TuninettiEleonora GhisoniSandro PignataElisa PicardoFrancesco RaspagliesiClaudia AndreettaElena MaldiGrazia ArtioliSerafina MammolitiLucia ZanchiAngelica SikokisNicoletta BigliaMaria Concetta FargnoliVincenzo Dario MandatoClaudia CarellaGennaro CormioMarco MarinaccioAndrea PuppoBiagio PaoliniLucia BorsottiGiulia ScottoMargherita TurinettoDario SangioloMassimo Di MaioGiorgio ValabregaPublished in: Cancers (2023)
Ki67 at diagnosis did not discriminate responders to PARPi.